Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Kwon MC, Thuring JW, Querolle O, Dai X, et al. Blood 2024;144:1206-1220.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kwon MC, Thuring JW, Querolle O, Dai X, et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood 2024;144:1206-1220.
PMID: 38905635